It has been reported to reduce the number of TAMs and increase the CD8+/CD4+ T cell ratio in diffuse-type giant cell tumor (dt-GCT) patients (a macrophage-rich tumor type), consequently delaying tumor growth [149], with effects reported also in soft tissue sarcoma, mesothelioma, ovarian, breast and pancreatic cancer patients [150]. Here, CD8A is linked to neoplasm.